{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:24:56Z","timestamp":1792783496055,"version":"4.5.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Australian Government Research Training Program (RTP) scholarship","id":[{"id":"https:\/\/ror.org\/0314h5y94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"UTS Chancellor\u2019s Research Fellowship"},{"name":"Moderna Global fellowship"},{"name":"NHMRC L3 Investigator grant"},{"DOI":"10.13039\/501100025520","name":"Medical Research Future Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100025520","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of New South Wales","id":[{"id":"https:\/\/ror.org\/03r8z3t63","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>SARS-CoV-2 continues to circulate globally, with persistent hospitalizations, despite a successful global vaccination strategy. We have developed highly conserved, antiviral short interfering (si)RNA and demonstrated in vivo antiviral efficacy following intranasal treatment of mice with naked siRNA. To enhance antiviral efficacy and siRNA protection, in this study we investigated the use of LNP packaging to improve delivery and efficacy. We examined three clinically approved lipid nanoparticle (LNP) formulations that mimic the compositions of Alnylam\u2019s Onpattro (MC3), Moderna\u2019s Spikevax (SM-102), and Pfizer-BioNTech\u2019s Comirnaty (ALC-0315) RNA-based therapeutics, to identify the optimal formulation for antiviral siRNA therapeutic respiratory delivery and antiviral efficacy. All LNP formulations assessed showed successful delivery of siRNA to respiratory cells in vitro and provided effective silencing of siRNA targeted SARS-CoV-2 genes. However, the MC3-based LNP-siRNA (MC3 LNP-siRNA) treatment elicited the least off-target immune activation, with no induction of interferon stimulated genes. Additionally, the MC3 LNP-siRNA remained effective when administered 24\u00a0h post-infection, significantly reducing viral RNA levels in vitro. Chemical modification of siRNA with 2\u2032\u2011O\u2011methyl incorporation further attenuated immune activation, without compromising efficacy. In vivo intranasal delivery of MC3 LNP-siRNA was generally well tolerated, with no adverse effects on body weight or pulmonary function at therapeutic doses, although mild pulmonary leukocyte infiltration was observed at higher or repeated doses. Our study demonstrates that LNP-encapsulated and chemically modified siRNAs can provide an effective and mutation-resilient antiviral strategy. This study compares clinically relevant LNP formulations for siRNA delivery to the respiratory tract, demonstrating that MC3-based LNPs offer a promising platform for safe and effective RNA therapeutic delivery.<\/jats:p>","DOI":"10.1007\/s13346-026-02076-y","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T18:26:25Z","timestamp":1771439185000},"page":"3848-3871","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative analysis of clinically approved lipid nanoparticles for intranasal siRNA delivery against SARS-CoV-2"],"prefix":"10.1007","volume":"16","author":[{"given":"Yuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt D.","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Ledger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Shipley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanshu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Moles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Turville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pall","family":"Thordarson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip M.","family":"Hansbro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kavallaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D.","family":"Kelleher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantelle L.","family":"Ahlenstiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"2076_CR1","doi-asserted-by":"publisher","unstructured":"Synowiec A, Szczepanski A, Barreto-Duran E, Lie LK, Pyrc K. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): a Systemic Infection. Clin Microbiol Rev. 2021;34(2). https:\/\/doi.org\/10.1128\/CMR.00133-20.","DOI":"10.1128\/CMR.00133-20"},{"issue":"20","key":"2076_CR2","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","volume":"383","author":"LA Jackson","year":"2020","unstructured":"Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med. 2020;383(20):1920\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2022483.","journal-title":"N Engl J Med"},{"issue":"1","key":"2076_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00406-4","volume":"6","author":"C Counoupas","year":"2021","unstructured":"Counoupas C, Johansen MD, Stella AO, Nguyen DH, Ferguson AL, Aggarwal A, et al. A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection. NPJ Vaccines. 2021;6(1):143. https:\/\/doi.org\/10.1038\/s41541-021-00406-4.","journal-title":"NPJ Vaccines"},{"key":"2076_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100208","volume":"10","author":"P Naaber","year":"2021","unstructured":"Naaber P, Tserel L, Kangro K, Sepp E, Jurjenson V, Adamson A, et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. The Lancet Regional Health - Europe. 2021;10:100208. https:\/\/doi.org\/10.1016\/j.lanepe.2021.100208.","journal-title":"The Lancet Regional Health - Europe"},{"key":"2076_CR5","unstructured":"Paxlovid for treatment of COVID-19. Med Lett Drugs Ther. 2022;64(1642):9\u201310."},{"key":"2076_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01684-5","author":"YY Syed","year":"2022","unstructured":"Syed YY. Molnupiravir: first approval. Drugs. 2022. https:\/\/doi.org\/10.1007\/s40265-022-01684-5.","journal-title":"Drugs"},{"key":"2076_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105252","volume":"198","author":"L Vangeel","year":"2022","unstructured":"Vangeel L, Chiu W, De Jonghe S, Maes P, Slechten B, Raymenants J, et al. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res. 2022;198:105252. https:\/\/doi.org\/10.1016\/j.antiviral.2022.105252.","journal-title":"Antiviral Res"},{"issue":"21","key":"2076_CR8","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","volume":"385","author":"A Gupta","year":"2021","unstructured":"Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody Sotrovimab. N Engl J Med. 2021;385(21):1941\u201350. https:\/\/doi.org\/10.1056\/NEJMoa2107934.","journal-title":"N Engl J Med"},{"issue":"9","key":"2076_CR9","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.5694\/mja2.51750","volume":"217","author":"A Polkinghorne","year":"2022","unstructured":"Polkinghorne A, Branley JM. Medications for early treatment of COVID-19 in Australia. Med J Aust. 2022;217(9):S7-13. https:\/\/doi.org\/10.5694\/mja2.51750.","journal-title":"Med J Aust"},{"issue":"12","key":"2076_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2024.102583","volume":"17","author":"W Yang","year":"2024","unstructured":"Yang W, Zhang W, Zhou J, Ma X, Wang C, Zhao M, et al. Comparison of the therapeutic effect of Paxlovid and Azvudine in the treatment of COVID-19: a retrospective study. J Infect Public Health. 2024;17(12):102583. https:\/\/doi.org\/10.1016\/j.jiph.2024.102583.","journal-title":"J Infect Public Health"},{"issue":"2","key":"2076_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.34172\/mejdd.2024.377","volume":"16","author":"F Seyedalipour","year":"2024","unstructured":"Seyedalipour F, Alipour S, Mehdinezhad H, Akrami R, Shirafkan H. Incidence of elevated liver enzyme levels in patients receiving remdesivir and its effective factors. Middle East J Dig Dis. 2024;16(2):109\u201313. https:\/\/doi.org\/10.34172\/mejdd.2024.377.","journal-title":"Middle East J Dig Dis"},{"issue":"7","key":"2076_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/jpc.16569","volume":"60","author":"T Jinda","year":"2024","unstructured":"Jinda T, Mizuno S, Tatami S, Kasai M, Ishida T. Risk factors for liver enzyme elevation with remdesivir use in the treatment of paediatric COVID-19. J Paediatr Child Health. 2024;60(7):299\u2013302. https:\/\/doi.org\/10.1111\/jpc.16569.","journal-title":"J Paediatr Child Health"},{"key":"2076_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102620","volume":"72","author":"WM Chu","year":"2024","unstructured":"Chu WM, Wan EYF, Ting Wong ZC, Tam AR, Kei Wong IC, Yin Chan EW, et al. Comparison of safety and efficacy between Nirmatrelvir-ritonavir and molnupiravir in the treatment of COVID-19 infection in patients with advanced kidney disease: a retrospective observational study. EClinicalMedicine. 2024;72:102620. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102620.","journal-title":"EClinicalMedicine"},{"issue":"6","key":"2076_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-064498","volume":"13","author":"JJ Petersen","year":"2023","unstructured":"Petersen JJ, Jorgensen CK, Faltermeier P, Siddiqui F, Feinberg J, Nielsen EE, et al. Drug interventions for prevention of COVID-19 progression to severe disease in outpatients: a systematic review with meta-analyses and trial sequential analyses (The LIVING Project). BMJ Open. 2023;13(6):e064498. https:\/\/doi.org\/10.1136\/bmjopen-2022-064498.","journal-title":"BMJ Open"},{"key":"2076_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9060557","author":"A Torrente-Lopez","year":"2021","unstructured":"Torrente-Lopez A, Hermosilla J, Navas N, Cuadros-Rodriguez L, Cabeza J, Salmeron-Garcia A. The relevance of monoclonal antibodies in the treatment of COVID-19. Vaccines. 2021. https:\/\/doi.org\/10.3390\/vaccines9060557.","journal-title":"Vaccines"},{"key":"2076_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2023.105677","volume":"217","author":"E Bowden-Reid","year":"2023","unstructured":"Bowden-Reid E, Ledger S, Zhang Y, Di Giallonardo F, Aggarwal A, Stella AO, et al. Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2. Antiviral Res. 2023;217:105677. https:\/\/doi.org\/10.1016\/j.antiviral.2023.105677.","journal-title":"Antiviral Res"},{"issue":"5","key":"2076_CR17","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1021\/acsomega.7b00291","volume":"2","author":"H Iribe","year":"2017","unstructured":"Iribe H, Miyamoto K, Takahashi T, Kobayashi Y, Leo J, Aida M, et al. Chemical modification of the siRNA seed region suppresses off-target effects by steric hindrance to base-pairing with targets. ACS Omega. 2017;2(5):2055\u201364. https:\/\/doi.org\/10.1021\/acsomega.7b00291.","journal-title":"ACS Omega"},{"key":"2076_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00331","volume":"8","author":"Z Meng","year":"2017","unstructured":"Meng Z, Lu M. RNA interference-induced innate immunity, off-target effect, or immune adjuvant? Front Immunol. 2017;8:331. https:\/\/doi.org\/10.3389\/fimmu.2017.00331.","journal-title":"Front Immunol"},{"key":"2076_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtchem.2023.101478","volume":"29","author":"R Solanki","year":"2023","unstructured":"Solanki R, Shankar A, Modi U, Patel S. New insights from nanotechnology in SARS-CoV-2 detection, treatment strategy, and prevention. Mater Today Chem. 2023;29:101478. https:\/\/doi.org\/10.1016\/j.mtchem.2023.101478.","journal-title":"Mater Today Chem"},{"key":"2076_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262311675","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Johansen MD, Ledger S, Turville S, Thordarson P, Hansbro PM, et al. Respiratory delivery of highly conserved antiviral siRNAs suppress SARS-CoV-2 infection. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms262311675.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2076_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1716153.","journal-title":"N Engl J Med"},{"issue":"25","key":"2076_CR22","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","volume":"383","author":"EE Walsh","year":"2020","unstructured":"Walsh EE, Frenck RW Jr., Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439\u201350. https:\/\/doi.org\/10.1056\/NEJMoa2027906.","journal-title":"N Engl J Med"},{"issue":"12","key":"2076_CR23","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078\u201394. https:\/\/doi.org\/10.1038\/s41578-021-00358-0.","journal-title":"Nat Rev Mater"},{"issue":"7","key":"2076_CR24","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1021\/acs.molpharmaceut.2c00033","volume":"19","author":"F Ferraresso","year":"2022","unstructured":"Ferraresso F, Strilchuk AW, Juang LJ, Poole LG, Luyendyk JP, Kastrup CJ. Comparison of DLin-MC3-DMA and ALC-0315 for siRNA delivery to hepatocytes and hepatic stellate cells. Mol Pharm. 2022;19(7):2175\u201382. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c00033.","journal-title":"Mol Pharm"},{"key":"2076_CR25","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/394578","author":"Y Zhu","year":"2010","unstructured":"Zhu Y, Chidekel A, Shaffer TH. Cultured human airway epithelial cells (calu-3): a model of human respiratory function, structure, and inflammatory responses. Crit Care Res Pract. 2010. https:\/\/doi.org\/10.1155\/2010\/394578.","journal-title":"Crit Care Res Pract"},{"issue":"1\u20132","key":"2076_CR26","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jviromet.2011.03.027","volume":"174","author":"JL Harcourt","year":"2011","unstructured":"Harcourt JL, Caidi H, Anderson LJ, Haynes LM. Evaluation of the Calu-3 cell line as a model of in vitro respiratory syncytial virus infection. J Virol Methods. 2011;174(1\u20132):144\u20139. https:\/\/doi.org\/10.1016\/j.jviromet.2011.03.027.","journal-title":"J Virol Methods"},{"key":"2076_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.1003608","volume":"12","author":"GA Pires De Souza","year":"2022","unstructured":"Pires De Souza GA, Le Bideau M, Boschi C, Wurtz N, Colson P, Aherfi S, et al. Choosing a cellular model to study SARS-CoV-2. Front Cell Infect Microbiol. 2022;12:1003608. https:\/\/doi.org\/10.3389\/fcimb.2022.1003608.","journal-title":"Front Cell Infect Microbiol"},{"key":"2076_CR28","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.jconrel.2024.02.007","volume":"367","author":"A Logan","year":"2024","unstructured":"Logan A, Howard CB, Huda P, Kimpton K, Ma Z, Thurecht KJ, et al. Targeted delivery of polo-like kinase 1 siRNA nanoparticles using an EGFR-PEG bispecific antibody inhibits proliferation of high-risk neuroblastoma. J Control Release. 2024;367:806\u201320. https:\/\/doi.org\/10.1016\/j.jconrel.2024.02.007.","journal-title":"J Control Release"},{"key":"2076_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115065","volume":"165","author":"O Escalona-Rayo","year":"2023","unstructured":"Escalona-Rayo O, Zeng Y, Knol RA, Kock TJF, Aschmann D, Slutter B, et al. In vitro and in vivo evaluation of clinically-approved ionizable cationic lipids shows divergent results between mRNA transfection and vaccine efficacy. Biomed Pharmacother. 2023;165:115065. https:\/\/doi.org\/10.1016\/j.biopha.2023.115065.","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"2076_CR30","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nbt0997-871","volume":"15","author":"R Zufferey","year":"1997","unstructured":"Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol. 1997;15(9):871\u20135. https:\/\/doi.org\/10.1038\/nbt0997-871.","journal-title":"Nat Biotechnol"},{"issue":"12","key":"2076_CR31","doi-asserted-by":"publisher","first-page":"9873","DOI":"10.1128\/JVI.72.12.9873-9880.1998","volume":"72","author":"R Zufferey","year":"1998","unstructured":"Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 1998;72(12):9873\u201380. https:\/\/doi.org\/10.1128\/JVI.72.12.9873-9880.1998.","journal-title":"J Virol"},{"issue":"1","key":"2076_CR32","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1073\/pnas.232688199","volume":"100","author":"XF Qin","year":"2003","unstructured":"Qin XF, An DS, Chen IS, Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci U S A. 2003;100(1):183\u20138. https:\/\/doi.org\/10.1073\/pnas.232688199.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2076_CR33","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202115298","volume":"14","author":"YC Chang","year":"2022","unstructured":"Chang YC, Yang CF, Chen YF, Yang CC, Chou YL, Chou HW, et al. A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant. EMBO Mol Med. 2022;14(4):e15298. https:\/\/doi.org\/10.15252\/emmm.202115298.","journal-title":"EMBO Mol Med"},{"issue":"9","key":"2076_CR34","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1038\/sj.mt.6300240","volume":"15","author":"M Robbins","year":"2007","unstructured":"Robbins M, Judge A, Liang L, McClintock K, Yaworski E, MacLachlan I. 2\u2019-O-methyl-modified RNAs act as TLR7 antagonists. Mol Ther. 2007;15(9):1663\u20139. https:\/\/doi.org\/10.1038\/sj.mt.6300240.","journal-title":"Mol Ther"},{"issue":"6","key":"2076_CR35","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1089\/oli.2010.0246","volume":"20","author":"NS Petrova Kruglova","year":"2010","unstructured":"Petrova Kruglova NS, Meschaninova MI, Venyaminova AG, Zenkova MA, Vlassov VV, Chernolovskaya EL. 2\u2019-O-methyl-modified anti-MDR1 fork-siRNA duplexes exhibiting high nuclease resistance and prolonged silencing activity. Oligonucleotides. 2010;20(6):297\u2013308. https:\/\/doi.org\/10.1089\/oli.2010.0246.","journal-title":"Oligonucleotides"},{"issue":"10","key":"2076_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2015.31","volume":"4","author":"C Ahlenstiel","year":"2015","unstructured":"Ahlenstiel C, Mendez C, Lim ST, Marks K, Turville S, Cooper DA, et al. Novel RNA duplex locks HIV-1 in a latent state via chromatin-mediated transcriptional silencing. Mol Ther Nucleic Acids. 2015;4(10):e261. https:\/\/doi.org\/10.1038\/mtna.2015.31.","journal-title":"Mol Ther Nucleic Acids"},{"key":"2076_CR37","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20240896","author":"W Awad","year":"2025","unstructured":"Awad W, Mayall JR, Xu W, Johansen MD, Patton T, Lim XY, et al. Cigarette smoke components modulate the MR1-MAIT axis. J Exp Med. 2025. https:\/\/doi.org\/10.1084\/jem.20240896.","journal-title":"J Exp Med"},{"key":"2076_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics10020057","author":"M Danaei","year":"2018","unstructured":"Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018. https:\/\/doi.org\/10.3390\/pharmaceutics10020057.","journal-title":"Pharmaceutics"},{"issue":"3","key":"2076_CR39","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s11095-006-9174-3","volume":"24","author":"AH Chow","year":"2007","unstructured":"Chow AH, Tong HH, Chattopadhyay P, Shekunov BY. Particle engineering for pulmonary drug delivery. Pharm Res. 2007;24(3):411\u201337. https:\/\/doi.org\/10.1007\/s11095-006-9174-3.","journal-title":"Pharm Res"},{"issue":"1","key":"2076_CR40","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1159\/000546141","volume":"11","author":"M Jia","year":"2025","unstructured":"Jia M, Han S, Li L, Fu Y, Zhou D. Interferon-stimulated genes: novel targets in renal pathogenesis. Kidney Dis (Basel). 2025;11(1):390\u2013401. https:\/\/doi.org\/10.1159\/000546141.","journal-title":"Kidney Dis (Basel)"},{"issue":"1","key":"2076_CR41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrd3010","volume":"9","author":"AL Jackson","year":"2010","unstructured":"Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov. 2010;9(1):57\u201367. https:\/\/doi.org\/10.1038\/nrd3010.","journal-title":"Nat Rev Drug Discov"},{"key":"2076_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fpls.2020.526455","volume":"11","author":"J Neumeier","year":"2020","unstructured":"Neumeier J, Meister G. SiRNA specificity: RNAi mechanisms and strategies to reduce off-target effects. Front Plant Sci. 2020;11:526455. https:\/\/doi.org\/10.3389\/fpls.2020.526455.","journal-title":"Front Plant Sci"},{"key":"2076_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2199-9-60","volume":"9","author":"C Tschuch","year":"2008","unstructured":"Tschuch C, Schulz A, Pscherer A, Werft W, Benner A, Hotz-Wagenblatt A, et al. Off-target effects of siRNA specific for GFP. BMC Mol Biol. 2008;9:60. https:\/\/doi.org\/10.1186\/1471-2199-9-60.","journal-title":"BMC Mol Biol"},{"key":"2076_CR44","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-025-01788-x","author":"E Bowden-Reid","year":"2025","unstructured":"Bowden-Reid E, Moles E, Kelleher A, Ahlenstiel C. Harnessing antiviral RNAi therapeutics for pandemic viruses: SARS-CoV-2 and HIV. Drug Deliv Transl Res. 2025. https:\/\/doi.org\/10.1007\/s13346-025-01788-x.","journal-title":"Drug Deliv Transl Res"},{"issue":"15","key":"2076_CR45","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","volume":"78","author":"SM Hoy","year":"2018","unstructured":"Hoy SM. Patisiran: first global approval. Drugs. 2018;78(15):1625\u201331. https:\/\/doi.org\/10.1007\/s40265-018-0983-6.","journal-title":"Drugs"},{"issue":"6","key":"2076_CR46","doi-asserted-by":"publisher","first-page":"677","DOI":"10.5858\/arpa.2021-0607-SA","volume":"146","author":"MT Kelliher","year":"2022","unstructured":"Kelliher MT, Levy JJ, Nerenz RD, Poore B, Johnston AA, Rogers AR, et al. Comparison of symptoms and antibody response following administration of Moderna or Pfizer SARS-CoV-2 vaccines. Arch Pathol Lab Med. 2022;146(6):677\u201385. https:\/\/doi.org\/10.5858\/arpa.2021-0607-SA.","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"2076_CR47","doi-asserted-by":"publisher","first-page":"34","DOI":"10.14740\/jh954","volume":"11","author":"S Sridhara","year":"2022","unstructured":"Sridhara S, Nair R, Stanek M. Severe aplastic anemia after receiving SARS-CoV-2 Moderna mRNA vaccination. J Hematol. 2022;11(1):34\u20139. https:\/\/doi.org\/10.14740\/jh954.","journal-title":"J Hematol"},{"issue":"3","key":"2076_CR48","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.14099","volume":"13","author":"SV Malayala","year":"2021","unstructured":"Malayala SV, Mohan G, Vasireddy D, Atluri P. Purpuric rash and thrombocytopenia after the mRNA-1273 (Moderna) COVID-19 vaccine. Cureus. 2021;13(3):e14099. https:\/\/doi.org\/10.7759\/cureus.14099.","journal-title":"Cureus"},{"issue":"13","key":"2076_CR49","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.2169\/internalmedicine.8711-21","volume":"61","author":"B Takase","year":"2022","unstructured":"Takase B, Hayashi K, Hisada T, Tsuchiya T, Masaki N, Nagata M. Chest pain with new abnormal electrocardiogram development after injection of COVID-19 vaccine manufactured by Moderna. Intern Med. 2022;61(13):2089\u201390. https:\/\/doi.org\/10.2169\/internalmedicine.8711-21.","journal-title":"Intern Med"},{"issue":"7","key":"2076_CR50","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1080\/09273948.2023.2239338","volume":"32","author":"D Dutt","year":"2024","unstructured":"Dutt D, Lam J, Richards J. Bilateral relentless placoid chorioretinitis following Pfizer-BioNTech COVID-19 vaccination: specific antigenic trigger or nonspecific immune activation? Ocul Immunol Inflamm. 2024;32(7):1498\u2013503. https:\/\/doi.org\/10.1080\/09273948.2023.2239338.","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"2076_CR51","doi-asserted-by":"publisher","first-page":"397","DOI":"10.4103\/ojo.ojo_354_21","volume":"15","author":"PP Shah","year":"2022","unstructured":"Shah PP, Gelnick S, Zhu D, Wong A, Verma R. Optic neuritis secondary to the Pfizer-BioNTech-162b2 COVID-19 vaccine managed with plasmapheresis: a case report and review. Oman J Ophthalmol. 2022;15(3):397\u2013402. https:\/\/doi.org\/10.4103\/ojo.ojo_354_21.","journal-title":"Oman J Ophthalmol"},{"issue":"12","key":"2076_CR52","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.20313","volume":"13","author":"TS Chachar","year":"2021","unstructured":"Chachar TS, Yousuf N, Sulaibikh L, Abdulqader F, Alqahtani M. First report of acute myocarditis post-Pfizer-BioNTech COVID-19 vaccination in the Kingdom of Bahrain. Cureus. 2021;13(12):e20313. https:\/\/doi.org\/10.7759\/cureus.20313.","journal-title":"Cureus"},{"key":"2076_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/v16071072","author":"J Sun","year":"2024","unstructured":"Sun J, Lu S, Xiao J, Xu N, Li Y, Xu J, et al. Inhibition of SARS-CoV-2 replication by self-assembled siRNA nanoparticles targeting multiple highly conserved viral sequences. Viruses. 2024. https:\/\/doi.org\/10.3390\/v16071072.","journal-title":"Viruses"},{"key":"2076_CR54","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.csbj.2025.03.034","volume":"27","author":"NS Taibe","year":"2025","unstructured":"Taibe NS, Mahmoud SH, Kord MA, Badawy MA, Shehata M, Elhefnawi M. In silico and in vitro development of novel small interfering RNAs (siRNAs) to inhibit SARS-CoV-2. Comput Struct Biotechnol J. 2025;27:1460\u201371. https:\/\/doi.org\/10.1016\/j.csbj.2025.03.034.","journal-title":"Comput Struct Biotechnol J"},{"issue":"7","key":"2076_CR55","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1016\/j.ymthe.2021.05.004","volume":"29","author":"A Idris","year":"2021","unstructured":"Idris A, Davis A, Supramaniam A, Acharya D, Kelly G, Tayyar Y, et al. A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19. Mol Ther. 2021;29(7):2219\u201326. https:\/\/doi.org\/10.1016\/j.ymthe.2021.05.004.","journal-title":"Mol Ther"},{"issue":"42","key":"2076_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202406211","volume":"11","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Liao Y, Fan L, Wei X, Huang Q, Yang C, et al. Lung-targeted lipid nanoparticle-delivered siUSP33 attenuates SARS-CoV-2 replication and virulence by promoting envelope degradation. Adv Sci. 2024;11(42):e2406211. https:\/\/doi.org\/10.1002\/advs.202406211.","journal-title":"Adv Sci"},{"key":"2076_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2024.105815","volume":"222","author":"A Idris","year":"2024","unstructured":"Idris A, Supramaniam A, Tayyar Y, Kelly G, McMillan NAJ, Morris KV. An intranasally delivered ultra-conserved siRNA prophylactically represses SARS-CoV-2 infection in the lung and nasal cavity. Antiviral Res. 2024;222:105815. https:\/\/doi.org\/10.1016\/j.antiviral.2024.105815.","journal-title":"Antiviral Res"},{"issue":"3","key":"2076_CR58","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jmii.2023.02.010","volume":"56","author":"A Supramaniam","year":"2023","unstructured":"Supramaniam A, Tayyar Y, Clarke DTW, Kelly G, Acharya D, Morris KV, et al. Prophylactic intranasal administration of lipid nanoparticle formulated siRNAs reduce SARS-CoV-2 and RSV lung infection. J Microbiol Immunol Infect. 2023;56(3):516\u201325. https:\/\/doi.org\/10.1016\/j.jmii.2023.02.010.","journal-title":"J Microbiol Immunol Infect"},{"key":"2076_CR59","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.2147\/IJN.S448005","volume":"19","author":"V Yathindranath","year":"2024","unstructured":"Yathindranath V, Safa N, Tomczyk MM, Dolinsky V, Miller DW. Lipid nanoparticle-based inhibitors for SARS-CoV-2 host cell infection. Int J Nanomedicine. 2024;19:3087\u2013108. https:\/\/doi.org\/10.2147\/IJN.S448005.","journal-title":"Int J Nanomedicine"},{"issue":"10","key":"2076_CR60","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.3109\/03639041003695113","volume":"36","author":"M Haghi","year":"2010","unstructured":"Haghi M, Young PM, Traini D, Jaiswal R, Gong J, Bebawy M. Time- and passage-dependent characteristics of a Calu-3 respiratory epithelial cell model. Drug Dev Ind Pharm. 2010;36(10):1207\u201314. https:\/\/doi.org\/10.3109\/03639041003695113.","journal-title":"Drug Dev Ind Pharm"},{"issue":"1\u20132","key":"2076_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0378-5173(00)00452-x","volume":"208","author":"KA Foster","year":"2000","unstructured":"Foster KA, Avery ML, Yazdanian M, Audus KL. Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery. Int J Pharm. 2000;208(1\u20132):1\u201311. https:\/\/doi.org\/10.1016\/s0378-5173(00)00452-x.","journal-title":"Int J Pharm"},{"key":"2076_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejps.2014.12.017","volume":"69","author":"ME Kreft","year":"2015","unstructured":"Kreft ME, Jerman UD, Lasic E, Hevir-Kene N, Rizner TL, Peternel L, et al. The characterization of the human cell line Calu-3 under different culture conditions and its use as an optimized in vitro model to investigate bronchial epithelial function. Eur J Pharm Sci. 2015;69:1\u20139. https:\/\/doi.org\/10.1016\/j.ejps.2014.12.017.","journal-title":"Eur J Pharm Sci"},{"key":"2076_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/v13122434","author":"JJ Baczenas","year":"2021","unstructured":"Baczenas JJ, Andersen H, Rashid S, Yarmosh D, Puthuveetil N, Parker M, et al. Propagation of SARS-CoV-2 in Calu-3 cells to eliminate mutations in the furin cleavage site of spike. Viruses. 2021. https:\/\/doi.org\/10.3390\/v13122434.","journal-title":"Viruses"},{"issue":"4","key":"2076_CR64","doi-asserted-by":"publisher","first-page":"e0119423","DOI":"10.1128\/mbio.01194-23","volume":"14","author":"M Li","year":"2023","unstructured":"Li M, Ayyanathan K, Dittmar M, Miller J, Tapescu I, Lee JS, et al. SARS-CoV-2 ORF6 protein does not antagonize interferon signaling in respiratory epithelial Calu-3 cells during infection. mBio. 2023;14(4):e0119423. https:\/\/doi.org\/10.1128\/mbio.01194-23.","journal-title":"mBio"},{"issue":"3","key":"2076_CR65","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1248\/bpb.b23-00689","volume":"47","author":"Y Liu","year":"2024","unstructured":"Liu Y, Suzuoki M, Tanaka H, Sakurai Y, Hatakeyama H, Akita H. Lymphatic endothelial cells produce chemokines in response to the lipid nanoparticles used in RNA vaccines. Biol Pharm Bull. 2024;47(3):698\u2013707. https:\/\/doi.org\/10.1248\/bpb.b23-00689.","journal-title":"Biol Pharm Bull"},{"issue":"4","key":"2076_CR66","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","volume":"23","author":"S Tahtinen","year":"2022","unstructured":"Tahtinen S, Tong AJ, Himmels P, Oh J, Paler-Martinez A, Kim L, et al. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat Immunol. 2022;23(4):532\u201342. https:\/\/doi.org\/10.1038\/s41590-022-01160-y.","journal-title":"Nat Immunol"},{"issue":"8","key":"2076_CR67","doi-asserted-by":"publisher","first-page":"11769","DOI":"10.1021\/acsnano.2c04543","volume":"16","author":"Y Ju","year":"2022","unstructured":"Ju Y, Lee WS, Pilkington EH, Kelly HG, Li S, Selva KJ, et al. Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine. ACS Nano. 2022;16(8):11769\u201380. https:\/\/doi.org\/10.1021\/acsnano.2c04543.","journal-title":"ACS Nano"},{"key":"2076_CR68","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jconrel.2021.11.042","volume":"341","author":"M Estape Senti","year":"2022","unstructured":"Estape Senti M, de Jongh CA, Dijkxhoorn K, Verhoef JJF, Szebeni J, Storm G, et al. Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement. J Control Release. 2022;341:475\u201386. https:\/\/doi.org\/10.1016\/j.jconrel.2021.11.042.","journal-title":"J Control Release"},{"issue":"9","key":"2076_CR69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221330","volume":"14","author":"H Calmet","year":"2019","unstructured":"Calmet H, Inthavong K, Eguzkitza B, Lehmkuhl O, Houzeaux G, Vazquez M. Nasal sprayed particle deposition in a human nasal cavity under different inhalation conditions. PLoS One. 2019;14(9):e0221330. https:\/\/doi.org\/10.1371\/journal.pone.0221330.","journal-title":"PLoS One"},{"key":"2076_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","volume":"15","author":"KJ Hassett","year":"2019","unstructured":"Hassett KJ, Benenato KE, Jacquinet E, Lee A, Woods A, Yuzhakov O, et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol Ther Nucleic Acids. 2019;15:1\u201311. https:\/\/doi.org\/10.1016\/j.omtn.2019.01.013.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"9","key":"2076_CR71","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1038\/s41565-025-01974-5","volume":"20","author":"S Omo-Lamai","year":"2025","unstructured":"Omo-Lamai S, Wang Y, Patel MN, Milosavljevic A, Zuschlag D, Poddar S, et al. Limiting endosomal damage sensing reduces inflammation triggered by lipid nanoparticle endosomal escape. Nat Nanotechnol. 2025;20(9):1285\u201397. https:\/\/doi.org\/10.1038\/s41565-025-01974-5.","journal-title":"Nat Nanotechnol"},{"key":"2076_CR72","doi-asserted-by":"publisher","unstructured":"Parua P, Ghosh S, Jana K, Seth A, Debnath B, Kumar Rout S, et al. Therapeutic potential of neutralizing monoclonal antibodies (nMAbs) against SARS-CoV-2 Omicron Variant. Curr Pharm Des. 2024. https:\/\/doi.org\/10.2174\/0113816128334441241108050528.","DOI":"10.2174\/0113816128334441241108050528"},{"issue":"11","key":"2076_CR73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1012625","volume":"20","author":"H Dong","year":"2024","unstructured":"Dong H, Zhou R, Chen J, Wei J, Wei Z, Yang Z, et al. Super broad and protective nanobodies against Sarbecoviruses including SARS-CoV-1 and the divergent SARS-CoV-2 subvariant KP.3.1.1. PLoS Pathog. 2024;20(11):e1012625. https:\/\/doi.org\/10.1371\/journal.ppat.1012625.","journal-title":"PLoS Pathog"},{"issue":"1","key":"2076_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s44298-024-00063-z","volume":"2","author":"MS Piepenbrink","year":"2024","unstructured":"Piepenbrink MS, Khalil AM, Chang A, Mostafa A, Basu M, Sarkar S, et al. Potent neutralization by a RBD antibody with broad specificity for SARS-CoV-2 JN.1 and other variants. Npj Viruses. 2024;2(1):55. https:\/\/doi.org\/10.1038\/s44298-024-00063-z.","journal-title":"Npj Viruses"},{"key":"2076_CR75","doi-asserted-by":"publisher","unstructured":"Stein SC, Hansen G, Ssebyatika G, Stroh LJ, Ochulor O, Herold E, et al. A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutation. J Virol. 2024;e0122324. https:\/\/doi.org\/10.1128\/jvi.01223-24.","DOI":"10.1128\/jvi.01223-24"},{"key":"2076_CR76","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae1195","author":"YI Anglero-Rodriguez","year":"2025","unstructured":"Anglero-Rodriguez YI, Lempp FA, Subramanian M, McIninch J, Schlegel MK, Bohan D, et al. High resistance barrier and prophylactic protection in preclinical models of SARS-CoV-2 with two siRNA combination. Nucleic Acids Res. 2025. https:\/\/doi.org\/10.1093\/nar\/gkae1195.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"2076_CR77","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.ymthe.2017.11.015","volume":"26","author":"D Alarcon-Aris","year":"2018","unstructured":"Alarcon-Aris D, Recasens A, Galofre M, Carballo-Carbajal I, Zacchi N, Ruiz-Bronchal E, et al. Selective \u03b1-synuclein knockdown in monoamine neurons by intranasal oligonucleotide delivery: potential therapy for Parkinson\u2019s disease. Mol Ther. 2018;26(2):550\u201367. https:\/\/doi.org\/10.1016\/j.ymthe.2017.11.015.","journal-title":"Mol Ther"},{"issue":"20","key":"2076_CR78","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.2217\/nnm-2020-0192","volume":"15","author":"E Landh","year":"2020","unstructured":"Landh E, Moir LM, Traini D, Young PM, Ong HX. Properties of rapamycin solid lipid nanoparticles for lymphatic access through the lungs & part II: the effect of nanoparticle charge. Nanomedicine (Lond). 2020;15(20):1947\u201363. https:\/\/doi.org\/10.2217\/nnm-2020-0192.","journal-title":"Nanomedicine (Lond)"},{"key":"2076_CR79","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jcis.2020.05.002","volume":"576","author":"JB Strachan","year":"2020","unstructured":"Strachan JB, Dyett BP, Nasa Z, Valery C, Conn CE. Toxicity and cellular uptake of lipid nanoparticles of different structure and composition. J Colloid Interface Sci. 2020;576:241\u201351. https:\/\/doi.org\/10.1016\/j.jcis.2020.05.002.","journal-title":"J Colloid Interface Sci"},{"issue":"2","key":"2076_CR80","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2217\/nnm.13.204","volume":"9","author":"HY Xue","year":"2014","unstructured":"Xue HY, Liu S, Wong HL. Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine. Nanomedicine. 2014;9(2):295\u2013312. https:\/\/doi.org\/10.2217\/nnm.13.204.","journal-title":"Nanomedicine"},{"issue":"1","key":"2076_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36295-5","volume":"14","author":"R Rouet","year":"2023","unstructured":"Rouet R, Henry JY, Johansen MD, Sobti M, Balachandran H, Langley DB, et al. Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients. Nat Commun. 2023;14(1):687. https:\/\/doi.org\/10.1038\/s41467-023-36295-5.","journal-title":"Nat Commun"},{"issue":"6","key":"2076_CR82","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1111\/all.15663","volume":"78","author":"M Khaitov","year":"2023","unstructured":"Khaitov M, Nikonova A, Kofiadi I, Shilovskiy I, Smirnov V, Elisytina O, et al. Treatment of COVID-19 patients with a SARS-CoV-2-specific siRNA-peptide dendrimer formulation. Allergy. 2023;78(6):1639\u201353. https:\/\/doi.org\/10.1111\/all.15663.","journal-title":"Allergy"},{"issue":"3","key":"2076_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102227","volume":"35","author":"M Tuttolomondo","year":"2024","unstructured":"Tuttolomondo M, Pham STD, Terp MG, Cendan Castillo V, Kalisi N, Vogel S, et al. A novel multitargeted self-assembling peptide-siRNA complex for simultaneous inhibition of SARS-CoV-2-host cell interaction and replication. Mol Ther Nucleic Acids. 2024;35(3):102227. https:\/\/doi.org\/10.1016\/j.omtn.2024.102227.","journal-title":"Mol Ther Nucleic Acids"},{"key":"2076_CR84","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jconrel.2022.03.039","volume":"345","author":"OM Merkel","year":"2022","unstructured":"Merkel OM. Can pulmonary RNA delivery improve our pandemic preparedness? J Control Release. 2022;345:549\u201356. https:\/\/doi.org\/10.1016\/j.jconrel.2022.03.039.","journal-title":"J Control Release"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02076-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-026-02076-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02076-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:57:31Z","timestamp":1790603851000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-026-02076-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":84,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2076"],"URL":"https:\/\/doi.org\/10.1007\/s13346-026-02076-y","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}